- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Biotech Breakthroughs
Global Pharmaceuticals & Biotech Biotech Breakthroughs
UPDATED Dec 05, 2023
Companys with strong funding and high growth potential
174 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ABEOAbeona Therapeutics | US$4.56 | -8.1% | 29.2% | US$114.9m | US$21.25 | PS31.7x | E64.5% | n/a | ||
| SAVACassava Sciences | US$21.30 | 2.7% | -36.6% | US$933.7m | US$124.00 | PB5.8x | E157.9% | n/a | ||
| CTKBCytek Biosciences | US$7.42 | 8.2% | -38.6% | US$997.6m | US$9.50 | PS5.5x | E105.5% | n/a | ||
| ENSCEnsysce Biosciences | US$0.94 | 15.4% | -96.5% | US$3.0m | US$12.25 | PB2x | E63.2% | n/a | ||
| IVBI.YInnovent Biologics | HK$20.89 | 0% | n/a | HK$67.2b | HK$28.19 | PS12.2x | E61.1% | n/a | ||
| PBIG.FParadigm Biopharmaceuticals | AU$0.26 | 0% | -76.5% | AU$148.1m | AU$1.52 | PS3166.6x | E86.1% | n/a | ||
| MVPMedical Developments International | AU$0.72 | -5.2% | -52.8% | AU$62.6m | AU$1.60 | PS1.9x | E45.0% | 0% | ||
| IMMImmutep | AU$0.31 | 6.9% | -12.7% | AU$368.5m | AU$1.26 | PS105.1x | E57.0% | n/a | ||
| MSBMesoblast | AU$0.32 | -22.9% | -67.5% | AU$260.4m | n/a | PS22.8x | E58.5% | n/a | ||
| LGPLittle Green Pharma | AU$0.13 | 4.2% | -30.6% | AU$37.5m | n/a | PS1.6x | E121.3% | n/a | ||
| 0QCOPharming Group | €1.08 | 2.6% | -7.5% | €723.0m | €1.86 | PS3.6x | E74.7% | n/a | ||
| 0L35Sarepta Therapeutics | US$88.01 | 7.3% | -26.4% | US$8.2b | US$139.02 | PS7.5x | E66.7% | n/a | ||
| 0HFRAnavex Life Sciences | US$8.14 | 15.0% | -4.3% | US$652.6m | US$48.12 | PB4.6x | E89.8% | n/a | ||
| CALTXSCalliditas Therapeutics | kr91.15 | 0% | -3.5% | kr4.9b | kr212.76 | PS4.2x | E61.4% | n/a | ||
| CYCCCyclacel Pharmaceuticals | US$0.31 | 3.6% | -57.7% | US$3.7m | US$13.67 | PS10x | E33.2% | n/a | ||
| CRMDCorMedix | US$3.54 | 5.4% | -10.6% | US$195.1m | US$14.25 | PS6530.1x | E62.3% | n/a | ||
| MDWDMediWound | US$9.00 | 5.9% | -4.8% | US$83.9m | US$28.00 | PS3.3x | E64.1% | n/a | ||
| TBPHTheravance Biopharma | US$10.69 | 3.0% | 1.5% | US$535.8m | US$14.50 | PS9.8x | E61.5% | n/a | ||
| PGENPrecigen | US$1.22 | 8.9% | -22.8% | US$303.7m | US$9.46 | PS44.9x | E50.4% | n/a | ||
| BFRIBiofrontera | US$3.79 | 0% | -81.2% | US$5.5m | US$20.00 | PB5.5x | E71.5% | n/a | ||
| 0IV3Geron | US$1.96 | -3.6% | -13.9% | US$1.1b | US$4.82 | PS3357.7x | E57.8% | n/a | ||
| IMMImmutep | AU$0.31 | 6.9% | -11.4% | AU$368.5m | AU$1.26 | PS105.1x | E57.0% | n/a | ||
| MEOB.FMesoblast | AU$0.25 | 0% | n/a | AU$256.3m | n/a | PS22.4x | E58.5% | n/a | ||
| PIQProteomics International Laboratories | AU$0.88 | 1.7% | -1.1% | AU$107.0m | AU$2.42 | PS33.7x | E59.9% | n/a |